公开(公告)号：US20140065610A1

公开(公告)日：2014-03-06

申请号：US13590211

申请日：2012-08-21

申请人： Laurent Essioux ,  Carsten Horn ,  Johann Karl ,  Peter Kastner ,  Fabian Model ,  Giuseppe Palermo ,  Christina Rabe ,  Daniel Umbricht ,  Gabriel Vargas ,  Anne Vogt

发明人： Laurent Essioux ,  Carsten Horn ,  Johann Karl ,  Peter Kastner ,  Fabian Model ,  Giuseppe Palermo ,  Christina Rabe ,  Daniel Umbricht ,  Gabriel Vargas ,  Anne Vogt

IPC分类号： G01N33/68 ,  C12Q1/68

CPC分类号： G01N33/6896 ,  C12Q1/6883 ,  G01N21/76 ,  G01N33/543 ,  G01N33/54366

摘要： An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI.

摘要翻译： 如果用甘氨酸再摄取抑制剂（GRI）进行治疗，预测具有神经发育，神经系统或神经精神障碍的患者是否将获得临床益处的体外方法，通过测定一，二，三，四五 或六个成员的补体因子H家族或其混合物或其组合，并与代表性值进行比较，其中患者样品中的蛋白质浓度的较高值代表代表性值，指示将从 用GRI治疗。